These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 15034576)

  • 1. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.
    Karp CL; Flick LM; Park KW; Softic S; Greer TM; Keledjian R; Yang R; Uddin J; Guggino WB; Atabani SF; Belkaid Y; Xu Y; Whitsett JA; Accurso FJ; Wills-Karp M; Petasis NA
    Nat Immunol; 2004 Apr; 5(4):388-92. PubMed ID: 15034576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystic fibrosis and lipoxins.
    Karp CL; Flick LM; Yang R; Uddin J; Petasis NA
    Prostaglandins Leukot Essent Fatty Acids; 2005; 73(3-4):263-70. PubMed ID: 15979866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiological impact of abnormal lipoxin A₄ production on cystic fibrosis airway epithelium and therapeutic potential.
    Higgins G; Ringholz F; Buchanan P; McNally P; Urbach V
    Biomed Res Int; 2015; 2015():781087. PubMed ID: 25866809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis.
    Philippe R; Urbach V
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30241412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications.
    Cohen-Cymberknoh M; Kerem E; Ferkol T; Elizur A
    Thorax; 2013 Dec; 68(12):1157-62. PubMed ID: 23704228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory cytokines in cystic fibrosis lung disease.
    Starosta V; Ratjen F; Rietschel E; Paul K; Griese M
    Eur Respir J; 2006 Sep; 28(3):581-7. PubMed ID: 16807263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of P2RY11 and ATP release by lipoxin A4 restores the airway surface liquid layer and epithelial repair in cystic fibrosis.
    Higgins G; Buchanan P; Perriere M; Al-Alawi M; Costello RW; Verriere V; McNally P; Harvey BJ; Urbach V
    Am J Respir Cell Mol Biol; 2014 Aug; 51(2):178-90. PubMed ID: 24588705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis.
    Ringholz FC; Buchanan PJ; Clarke DT; Millar RG; McDermott M; Linnane B; Harvey BJ; McNally P; Urbach V
    Eur Respir J; 2014 Aug; 44(2):394-404. PubMed ID: 24696116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoxin A(4) and interleukin-8 levels in cystic fibrosis sputum after antibiotherapy.
    Chiron R; Grumbach YY; Quynh NV; Verriere V; Urbach V
    J Cyst Fibros; 2008 Nov; 7(6):463-8. PubMed ID: 18541460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of n-3 PUFA on chronic airway inflammatory diseases.
    Giudetti AM; Cagnazzo R
    Prostaglandins Other Lipid Mediat; 2012 Dec; 99(3-4):57-67. PubMed ID: 23064030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How the airway smooth muscle in cystic fibrosis reacts in proinflammatory conditions: implications for airway hyper-responsiveness and asthma in cystic fibrosis.
    McCuaig S; Martin JG
    Lancet Respir Med; 2013 Apr; 1(2):137-47. PubMed ID: 24429094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia and sterile inflammation in cystic fibrosis airways: mechanisms and potential therapies.
    Montgomery ST; Mall MA; Kicic A; Stick SM;
    Eur Respir J; 2017 Jan; 49(1):. PubMed ID: 28052955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Disease: leukotrienes and lipoxins in scleroderma lung disease--insights and potential therapeutic implications.
    Kowal-Bielecka O; Kowal K; Distler O; Gay S
    Nat Clin Pract Rheumatol; 2007 Jan; 3(1):43-51. PubMed ID: 17203008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms and markers of airway inflammation in cystic fibrosis.
    De Rose V
    Eur Respir J; 2002 Feb; 19(2):333-40. PubMed ID: 11866015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis.
    Knowles MR; Hohneker KW; Zhou Z; Olsen JC; Noah TL; Hu PC; Leigh MW; Engelhardt JF; Edwards LJ; Jones KR
    N Engl J Med; 1995 Sep; 333(13):823-31. PubMed ID: 7544439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoxins: potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease.
    Kieran NE; Maderna P; Godson C
    Kidney Int; 2004 Apr; 65(4):1145-54. PubMed ID: 15086453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defective fluid transport by cystic fibrosis airway epithelia.
    Smith JJ; Karp PH; Welsh MJ
    J Clin Invest; 1994 Mar; 93(3):1307-11. PubMed ID: 8132771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapeutic key for cystic fibrosis: a role for lipoxins.
    Takai D; Nagase T; Shimizu T
    Nat Immunol; 2004 Apr; 5(4):357-8. PubMed ID: 15052263
    [No Abstract]   [Full Text] [Related]  

  • 19. Airway epithelial cell inflammatory signalling in cystic fibrosis.
    Jacquot J; Tabary O; Le Rouzic P; Clement A
    Int J Biochem Cell Biol; 2008; 40(9):1703-15. PubMed ID: 18434235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Developments in Cystic Fibrosis Airway Inflammation.
    Palaniyar N; Mall MA; Taube C; Worgall S; Grasemann H
    Mediators Inflamm; 2015; 2015():769425. PubMed ID: 26221065
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.